{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T17:46:21Z","timestamp":1770572781759,"version":"3.49.0"},"reference-count":42,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T00:00:00Z","timestamp":1714953600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Vertex Pharmaceuticals Incorporated","award":["no award\/grant number"],"award-info":[{"award-number":["no award\/grant number"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Thorax"],"accepted":{"date-parts":[[2024,2,12]]},"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Ivacaftor (IVA) improves lung function and other extrapulmonary outcomes in people with cystic fibrosis (CF). However, the effect of initiating IVA at earlier versus later ages has not been studied.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted an observational cohort study of people in the US CF Foundation Patient Registry aged \u22656 years with \u22651\u2009CF transmembrane conductance regulator\u2013gating mutation to compare the effects of initiating IVA at earlier ages on per cent predicted forced expiratory volume in 1\u2009s (ppFEV<jats:sub>1<\/jats:sub>) and pulmonary exacerbation (PEx) outcomes. People with CF were grouped by age at IVA initiation (ages 6\u201310, 11\u201315, 16\u201320 and 21\u201325 years) to perform three analyses of younger versus older IVA initiation (6\u201310 vs 11\u201315, 11\u201315 vs 16\u201320 and 16\u201320 vs 21\u201325 years). For each analysis, baseline characteristics assessed over 1-year periods at the same age prior to IVA initiation were balanced by standardised mortality\/morbidity ratio (SMR) weighting. For each analysis, outcomes were compared over a 5-year outcome assessment period when both groups were in the same age range and receiving IVA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Findings<\/jats:title><jats:p>Baseline characteristics were well balanced between younger and older IVA initiator groups after SMR weighting. In the outcome assessment period, younger IVA initiators had significantly higher mean ppFEV<jats:sub>1<\/jats:sub>than older initiators across all comparisons, and those initiating IVA between ages 6\u201310 and 11\u201315 years had significantly lower PEx rates.<\/jats:p><\/jats:sec><jats:sec><jats:title>Interpretation<\/jats:title><jats:p>Study findings showed the importance of early IVA initiation in people with CF.<\/jats:p><\/jats:sec>","DOI":"10.1136\/thorax-2023-220559","type":"journal-article","created":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T17:21:00Z","timestamp":1715016060000},"page":"915-924","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Impact of age at ivacaftor initiation on pulmonary outcomes among people with cystic fibrosis"],"prefix":"10.1136","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9283-3928","authenticated-orcid":false,"given":"Christian A","family":"Merlo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa J","family":"McGarry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teja","family":"Thorat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maral","family":"DerSarkissian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aruna","family":"Muthukumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joe","family":"Healy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M Alan","family":"Brookhart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaime L","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,5,6]]},"reference":[{"key":"2025012402150922000_79.10.915.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32542-3"},{"key":"2025012402150922000_79.10.915.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2015.09.008"},{"key":"2025012402150922000_79.10.915.3","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2011-200912"},{"key":"2025012402150922000_79.10.915.4","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1164\/rccm.201507-1409OC","article-title":"Lung clearance index and structural lung disease on computed tomography in early cystic fibrosis","volume":"193","author":"Ramsey","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"2025012402150922000_79.10.915.5","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-74502-1","article-title":"Lung function over the life course of paediatric and adult patients with cystic fibrosis from a large multi-centre registry","volume":"10","author":"Earnest","year":"2020","journal-title":"Sci Rep"},{"key":"2025012402150922000_79.10.915.6","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(16)00576-6"},{"key":"2025012402150922000_79.10.915.7","unstructured":"Cystic Fibrosis Foundation . Patient Registry 2021 annual data report; 2022. Available: https:\/\/www.cff.org\/about-us\/annual-report [Accessed 26 Jan 2023]."},{"key":"2025012402150922000_79.10.915.8","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-41868-x","article-title":"Cystic fibrosis-related mortality in the United States from 1999 to 2020: an observational analysis of time trends and disparities","volume":"13","author":"Singh","year":"2023","journal-title":"Sci Rep"},{"key":"2025012402150922000_79.10.915.9","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-2600(16)00053-9","article-title":"Newborn screening for cystic fibrosis","volume":"4","author":"Castellani","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2025012402150922000_79.10.915.10","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2020.608821","article-title":"Early diagnosis and intervention in cystic fibrosis: imagining the unimaginable","volume":"8","author":"Coverstone","year":"2020","journal-title":"Front Pediatr"},{"key":"2025012402150922000_79.10.915.11","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: a global perspective","volume":"8","author":"Bell","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2025012402150922000_79.10.915.12","unstructured":"Kalydeco (Ivacaftor) prescribing information. Vertex pharmaceuticals incorporated Boston, MA; 2012."},{"key":"2025012402150922000_79.10.915.13","unstructured":"Kalydeco (Ivacaftor) prescribing information. Vertex pharmaceuticals incorporated Boston, MA; 2020."},{"key":"2025012402150922000_79.10.915.14","unstructured":"Vertex . Vertex ANNOUNCES U.S. FDA approval for KALYDECO\u00ae (Ivacaftor) to treat eligible infants with CF ages 1 month and older. Vertex Press Release; 2023."},{"key":"2025012402150922000_79.10.915.15","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10071527","article-title":"Real-world outcomes of Ivacaftor treatment in people with cystic fibrosis: a systematic review","volume":"10","author":"Duckers","year":"2021","journal-title":"J Clin Med"},{"key":"2025012402150922000_79.10.915.16","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-43652-2","article-title":"A systematic review of the clinical efficacy and safety of CFTR modulators in cystic fibrosis","volume":"9","author":"Habib","year":"2019","journal-title":"Sci Rep"},{"key":"2025012402150922000_79.10.915.17","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jcf.2019.05.015","article-title":"Disease progression in patients with cystic fibrosis treated with Ivacaftor: data from national US and UK registries","volume":"19","author":"Volkova","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2025012402150922000_79.10.915.18","doi-asserted-by":"crossref","unstructured":"Merlo C , DerSarkissian M , Nguyen C , et al . Long-term impact of Ivacaftor on health outcomes and mortality risk of people with cystic fibrosis [In press]. 2024.","DOI":"10.1136\/thorax-2023-220558"},{"key":"2025012402150922000_79.10.915.19","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1164\/rccm.201606-1107CI","article-title":"Early lung disease in infants and preschool children with cystic fibrosis. What have we learned and what should we do about it","volume":"195","author":"Ranganathan","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2025012402150922000_79.10.915.20","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201511-781OC"},{"key":"2025012402150922000_79.10.915.21","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.113.000359"},{"key":"2025012402150922000_79.10.915.22","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood.2021014375","article-title":"Comparative effectiveness of ZUMA-5 (Axi-Cel) vs SCHOLAR-5 external control in relapsed\/refractory follicular lymphoma","volume":"140","author":"Ghione","year":"2022","journal-title":"Blood"},{"key":"2025012402150922000_79.10.915.23","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12197"},{"key":"2025012402150922000_79.10.915.24","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201301-0153OC"},{"key":"2025012402150922000_79.10.915.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105185"},{"key":"2025012402150922000_79.10.915.26","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6793-12-1"},{"key":"2025012402150922000_79.10.915.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2007.03.006"},{"key":"2025012402150922000_79.10.915.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.prrv.2016.03.002"},{"key":"2025012402150922000_79.10.915.29","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00159111"},{"key":"2025012402150922000_79.10.915.30","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2011.161117"},{"key":"2025012402150922000_79.10.915.31","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2012-202342"},{"key":"2025012402150922000_79.10.915.32","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2006.060889"},{"key":"2025012402150922000_79.10.915.33","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1164\/rccm.201802-0243LE","article-title":"Changes in lung clearance index in preschool-aged patients with cystic fibrosis treated with ivacaftor (GOAL): a clinical trial","volume":"198","author":"Ratjen","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2025012402150922000_79.10.915.34","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201503-0578OC"},{"key":"2025012402150922000_79.10.915.35","doi-asserted-by":"crossref","unstructured":"Higgins M , Volkova N , Farietta T , et al . Long-term benefits of early initiation of Ivacaftor (IVA) in people with cystic fibrosis (CF): interim results from an ongoing Registry-based study. ERS International Congress 2022 abstracts; 4 September Barcelona, Spain, 2022 doi:10.1183\/13993003.congress-2022.813","DOI":"10.1183\/13993003.congress-2022.813"},{"key":"2025012402150922000_79.10.915.36","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1164\/rccm.202008-3177OC","article-title":"Ivacaftor in infants aged 4 to< 12 months with cystic fibrosis and a gating mutation. results of a two-part phase 3 clinical trial","volume":"203","author":"Davies","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2025012402150922000_79.10.915.37","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2213-2600(18)30202-9","article-title":"Ivacaftor treatment of cystic fibrosis in children aged 12 to< 24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study","volume":"6","author":"Rosenfeld","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2025012402150922000_79.10.915.38","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.jcf.2023.03.002","article-title":"Real-world safety and effectiveness of elexacaftor\/tezacaftor\/Ivacaftor in people with cystic fibrosis: interim results of a long-term registry-based study","volume":"22","author":"Bower","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2025012402150922000_79.10.915.39","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32597-8"},{"key":"2025012402150922000_79.10.915.40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908639"},{"key":"2025012402150922000_79.10.915.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2023.02.009"},{"key":"2025012402150922000_79.10.915.42","first-page":"1146","article-title":"Rate of uptake of Ivacaftor use after US food and drug administration approval among patients enrolled in the US cystic fibrosis foundation patient registry","volume":"12","author":"Sawicki","year":"2015","journal-title":"Ann Am Thorac Soc"}],"container-title":["Thorax"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/thorax-2023-220559","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T10:16:34Z","timestamp":1737713794000},"score":1,"resource":{"primary":{"URL":"https:\/\/thorax.bmj.com\/lookup\/doi\/10.1136\/thorax-2023-220559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,6]]},"references-count":42,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,9,18]]},"published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.1136\/thorax-2023-220559"],"URL":"https:\/\/doi.org\/10.1136\/thorax-2023-220559","relation":{},"ISSN":["0040-6376","1468-3296"],"issn-type":[{"value":"0040-6376","type":"print"},{"value":"1468-3296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,6]]}}}